MarketCap
Facebook
X
TelegramAnnual report 2024
added 01-17-2026
Cellectis S.A. P/E Ratio 2011-2026 | CLLS
Annual P/E Ratio Cellectis S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -1.62 | -11.3 | -6.21 | -9.26 | -11.2 | -9.67 | -34 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.62 | -34 | -11.9 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biogen
BIIB
|
11.9 | $ 172.65 | 0.62 % | $ 25.1 B |  USA |
 |
MorphoSys AG
MOR
|
-0.612 | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
-2.63 | $ 2.38 | -4.22 % | $ 134 M |  China |
 |
Acorda Therapeutics
ACOR
|
-0.0662 | - | -24.86 % | $ 820 K | USA |
 |
BioNTech SE
BNTX
|
6.11 | $ 117.22 | 1.07 % | $ 27.2 B | Germany |
 |
Aptorum Group Limited
APM
|
-0.958 | $ 0.98 | 1.35 % | $ 5.34 M | China |
 |
Alterity Therapeutics Limited
ATHE
|
-66.5 | $ 3.62 | 1.91 % | $ 8.71 B |  Australia |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
55.7 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M |  France |
 |
Catalyst Biosciences
CBIO
|
-0.393 | $ 12.1 | -5.47 % | $ 797 M | USA |
 |
Midatech Pharma plc
MTP
|
-14.5 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.57 | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
-12.9 | - | - | $ 3.67 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-0.0902 | $ 1.78 | -2.47 % | $ 4.51 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-50 | $ 3.05 | -1.77 % | $ 908 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
-0.175 | - | - | $ 10.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-19.2 | $ 232.9 | -1.06 % | $ 5 B |  Danmark |
 |
Burford Capital Limited
BUR
|
12.2 | $ 9.73 | -0.21 % | $ 1.57 B | Britain |
 |
ARCA biopharma
ABIO
|
-5.78 | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-4.26 | - | 4.01 % | $ 150 M |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
-3.83 K | $ 67.14 | 0.13 % | $ 8.98 B | USA |
 |
Compugen Ltd.
CGEN
|
-10.4 | $ 2.05 | -1.91 % | $ 184 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
-400 | $ 4.4 | -2.87 % | $ 9.57 B | Israel |
 |
Aeterna Zentaris
AEZS
|
-4.94 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-0.00095 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-3.48 | - | - | $ 1.01 B | USA |
 |
Akouos
AKUS
|
-1.98 | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-18 | - | -15.15 % | $ 60.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
8.2 | $ 26.56 | 2.45 % | $ 1.29 B | USA |
 |
Coherus BioSciences
CHRS
|
-0.879 | $ 2.25 | 9.22 % | $ 212 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
-24.7 | $ 13.58 | 1.42 % | $ 4.2 B | USA |
 |
AIkido Pharma
AIKI
|
-1.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-15.8 | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-8.58 | - | - | $ 867 M | Germany |
 |
Aptose Biosciences
APTO
|
-0.0913 | - | -45.71 % | $ 1.2 M | Canada |
 |
Acer Therapeutics
ACER
|
-0.463 | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
-0.791 | - | -13.39 % | $ 1.45 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-4.65 | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-0.833 | - | 4.14 % | $ 49.1 M | USA |
 |
Athira Pharma
ATHA
|
-0.167 | - | - | $ 269 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-0.077 | - | -11.43 % | $ 502 K | USA |
 |
Celldex Therapeutics
CLDX
|
-0.00833 | $ 26.54 | 2.41 % | $ 1.71 M | USA |
 |
AVROBIO
AVRO
|
4.63 | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-0.203 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-1.16 | $ 2.75 | 1.84 % | $ 17.3 M | USA |
 |
AstraZeneca PLC
AZN
|
706 | $ 94.2 | 1.34 % | $ 96.9 B | Britain |
 |
Arena Pharmaceuticals
ARNA
|
-9.16 | - | -6.81 % | $ 3.04 B | USA |
 |
Brickell Biotech
BBI
|
-2 | - | -5.38 % | $ 6.06 M | USA |